Published in Mol Ther on February 02, 2010
Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res (2011) 2.39
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol (2014) 1.48
Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs. ACS Chem Biol (2010) 0.94
RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol (2012) 0.90
Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther (2011) 0.87
siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Res (2013) 0.83
Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One (2012) 0.81
siRNA for Influenza Therapy. Viruses (2010) 0.80
RNA interference for the treatment of papillomavirus disease. Open Virol J (2012) 0.80
Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther (2011) 0.80
EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics (2015) 0.79
Inosine-mediated modulation of RNA sensing by Toll-like receptor 7 (TLR7) and TLR8. J Virol (2013) 0.78
Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors. Nucleic Acids Res (2014) 0.78
The Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano (2017) 0.77
Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. PLoS One (2011) 0.77
Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. Transfus Med Hemother (2016) 0.75
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant? Front Immunol (2017) 0.75
Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice. PLoS One (2016) 0.75
Development of Novel Small Hairpin RNAs That do not Require Processing by Dicer or AGO2. Mol Ther (2016) 0.75
Prediction of Immunomodulatory potential of an RNA sequence for designing non-toxic siRNAs and RNA-based vaccine adjuvants. Sci Rep (2016) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol (2008) 16.65
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol (2009) 11.50
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell (2005) 9.35
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol (2005) 5.60
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2005) 3.28
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41
Immortalization of cloned mouse splenic macrophages with a retrovirus containing the v-raf/mil and v-myc oncogenes. Cell Immunol (1988) 2.38
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 2.06
Chemical modification of siRNAs for in vivo use. Oligonucleotides (2008) 2.03
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol (2005) 1.93
Activation of the mammalian immune system by siRNAs. Nat Biotechnol (2005) 1.86
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
Development of novel treatments for hepatitis C. Lancet Infect Dis (2009) 1.80
Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol (2008) 1.78
Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol (2006) 1.76
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev (2007) 1.48
Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol (2006) 1.27
Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol (2009) 1.25
TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol (2008) 1.25
Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol (2008) 1.22
Death mechanisms in cultured cells infected by Semliki Forest virus. J Gen Virol (1997) 1.04
Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res (2008) 1.03
Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol (2009) 0.98
Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Deliv Rev (2007) 0.97
The pharmacology of endosomal TLR agonists in viral disease. Biochem Soc Trans (2007) 0.94
Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opin Biol Ther (2009) 0.87
Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat (2007) 0.87
Virulence of a mouse-adapted Semliki Forest virus strain is associated with reduced susceptibility to interferon. J Gen Virol (2007) 0.87
Drug delivery-mediated control of RNA immunostimulation. Mol Ther (2009) 0.86
Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther (2009) 0.82
siRNA delivery not Toll-free. Nat Biotechnol (2009) 0.81
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol (2008) 16.65
IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol (2003) 15.67
AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature (2009) 13.23
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol (2010) 8.97
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol (2009) 8.40
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol (2010) 7.47
RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol (2009) 6.97
LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med (2003) 5.97
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol (2002) 4.63
HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest (2005) 3.93
Intracellular DNA recognition. Nat Rev Immunol (2010) 3.70
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature (2012) 3.67
The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity (2008) 3.50
A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol (2006) 3.46
The sterile inflammatory response. Annu Rev Immunol (2010) 3.45
Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci U S A (2007) 3.41
Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science (2008) 3.38
ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res (2006) 3.33
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07
Effects of sodium ions on DNA duplex oligomers: improved predictions of melting temperatures. Biochemistry (2004) 3.00
p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol (2003) 2.97
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem (2002) 2.61
Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity (2012) 2.58
Inflammasomes: too big to miss. J Clin Invest (2009) 2.51
The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem (2005) 2.47
Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut (2010) 2.42
ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res (2003) 2.39
Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res (2011) 2.39
CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol (2013) 2.38
Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol (2002) 2.37
Viral apoptosis is induced by IRF-3-mediated activation of Bax. EMBO J (2010) 2.36
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes. Immunity (2010) 2.29
Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem (2010) 2.23
Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem (2004) 2.21
Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature (2013) 2.16
Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab (2011) 2.16
The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci U S A (2006) 2.13
ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl) (2009) 2.08
Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis (2003) 2.05
Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A (2004) 2.04
Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol (2002) 2.00
TLR-independent type I interferon induction in response to an extracellular bacterial pathogen via intracellular recognition of its DNA. Cell Host Microbe (2008) 1.98
Hybridization kinetics and thermodynamics of molecular beacons. Nucleic Acids Res (2003) 1.88
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol (2010) 1.87
Activation of the mammalian immune system by siRNAs. Nat Biotechnol (2005) 1.86
An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem (2009) 1.85
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J Virol (2004) 1.81
Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem (2003) 1.78
miRNAs control insulin content in pancreatic β-cells via downregulation of transcriptional repressors. EMBO J (2011) 1.75
Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. Nat Protoc (2006) 1.74
Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol (2012) 1.71
Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol (2007) 1.69
NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol (2011) 1.69
Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol (2002) 1.66
Predicting stability of DNA duplexes in solutions containing magnesium and monovalent cations. Biochemistry (2008) 1.63
Role of PKR and Type I IFNs in viral control during primary and secondary infection. PLoS Pathog (2010) 1.63
Regulation of actin dynamics by protein kinase R control of gelsolin enforces basal innate immune defense. Immunity (2012) 1.62
Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol (2006) 1.61
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One (2012) 1.60
Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res (2006) 1.59
A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. Proc Natl Acad Sci U S A (2005) 1.56
The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem (2003) 1.55
Patterns of coordinate down-regulation of ARE-containing transcripts following immune cell activation. Genomics (2004) 1.54
Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology (2005) 1.54
Structure-function relationships of shared-stem and conventional molecular beacons. Nucleic Acids Res (2002) 1.51
The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev (2007) 1.48
Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther (2008) 1.47
Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol (2007) 1.45
Effects of fluorescent dyes, quenchers, and dangling ends on DNA duplex stability. Biochem Biophys Res Commun (2005) 1.44
Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol (2006) 1.44
A miR-19 regulon that controls NF-κB signaling. Nucleic Acids Res (2012) 1.43
Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res (2004) 1.43
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma (2012) 1.43
Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol (2005) 1.42
Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS Pathog (2013) 1.39
Phospholipid scramblase 1 potentiates the antiviral activity of interferon. J Virol (2004) 1.39
Heterogeneity in control of mRNA stability by AU-rich elements. J Biol Chem (2003) 1.37
A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34